AzurRx clips its IPO price, but manages to get the job done

These days, completing a biotech IPO often means settling for less. And AzurRx BioPharma is lowering its sights to a micro offering worth about $5 million.

The Brooklyn, NY-based biotech shrugged off its earlier range of $6 to $8 a share, settling for $5.50 on a little less than a million shares. The biotech plans to use the cash to back its work on non-systemic GI drugs.

Biotech IPOs have had a rocky experience this year, the natural result of the end of the gangbuster reception that greeted these offerings for the previous three years. But, one way or another, several are getting done.

AzurRx will trade as $AZRX.

One of the big IPOs on the radar for the 4th quarter is CRISPR Therapeutics, which will attempt to follow successful outings by rivals Editas and Intellia, which are also attempting to pioneer gene editing tech in the clinic.

Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 13,500+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy